Tumori, oncologa Del Mastro: "Sacituzumab govitecan opzione per cancro seno metastatico triplo negativo"

1 year ago

(Adnkronos) - “Ogni anno in Italia sono circa 13 mila i nuovi casi di carcinoma mammario metastatico e si stima che oggi in Italia ci sono circa 40 mila donne che convivono con questa diagnosi”. Per queste pazienti, “sacituzumab govitecan è un nuovo farmaco che ha dimostrato di migliorare l’aspettativa e la qualità di vita, rispetto ai trattamenti chemioterapici standard”. Lo ha detto Lucia Del Mastro, direttore della clinica di Oncologia medica dell’ospedale policlinico San Martino di Genova, all'incontro con la stampa ‘Gilead per le donne. Nuove prospettive nel tumore al seno metastatico’, che si è svolto Milano, durante il quale è stata annunciata l’estensione di indicazione del farmaco anticorpo-coniugato nel tumore al seno metastatico Hr+/Her2 e in seconda linea per il triplo negativo.

Transcript

00:00Every year in Italy there are about 13,000 new cases of metastatic mammary carcinoma,

00:09so every year in Italy this number of women is diagnosed with a metastatic tumour.

00:15It is estimated that today in Italy there are about 40,000 women who live with a metastatic mammary carcinoma diagnosis.

00:23In recent years, thanks to the introduction of new drugs,

00:27thanks also to a better knowledge of the biology of the mammary tumour,

00:31we have understood that there is not a single type of mammary tumour,

00:34but there are at least three different subtypes that have a different prognosis

00:39and that require different therapeutic options.

00:42Thanks to this knowledge and innovation, we have had a clear improvement

00:46of the life expectancy of the metastatic mammary tumour.

00:50The only subtype in which we had not observed an improvement in survival

00:54is the so-called triple negative subtype,

00:57that is, that tumour that does not benefit from anti-hormonal therapy

01:01and does not benefit from anti-HER2 treatments.

01:04And it is precisely in this subgroup of patients that this new drug,

01:08which is Sacitutum amagovitagan, has shown to improve the life expectancy,

01:13therefore to improve survival, to improve the time

01:17in which we are able to maintain the metastatic disease under control

01:21and also to improve the quality of life compared to standard chemotherapeutic treatments.

01:26We will be able to use this drug, Sacitutum amagovitagan,

01:31also in an earlier phase of the history of these women with the so-called triple negative

01:36mammary tumour, and therefore we expect that this earlier use

01:41can further improve the therapeutic results obtained so far.

01:46But Sacitutum amagovitagan will also have a new indication,

01:51which is the possibility of using it also in the subgroup with positive hormonal receptors,

01:56which constitutes the majority of cases of metastatic carcinoma.

02:00Also in these patients, compared to standard chemotherapy,

02:04this innovative drug, which is a conjugated antibody,

02:07has shown to improve both survival and quality of life.

02:12Therefore, it is an important therapeutic option for the majority of women

02:18who today live with metastatic carcinoma in Italy.

Tumori, oncologa Del Mastro: "Sacituzumab govitecan opzione per cancro seno metastatico triplo negativo"

Category

Transcript

Comments

Recommended